Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:DARE NASDAQ:GTBP NASDAQ:LIXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.58-1.6%$5.18$3.76▼$19.35$48.02M1.25116,069 shs7,600 shsDAREDare Bioscience$2.74-5.9%$1.87$1.27▼$9.19$39.60M1.09372,798 shs235,561 shsGTBPGT Biopharma$0.38-1.9%$0.41$0.26▼$3.85$13.50M0.641.03 million shs108,749 shsLIXTLixte Biotechnology$5.07+2.9%$3.17$0.64▼$6.26$58.93M1.0460,826 shs11,962 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.24%+5.59%+16.19%+6.18%-53.39%DAREDare Bioscience-7.91%+27.63%+64.41%+72.19%+0.66%GTBPGT Biopharma-3.28%+26.38%-5.76%-27.72%-83.39%LIXTLixte Biotechnology+12.05%+40.86%+72.98%+67.12%+313.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.58-1.6%$5.18$3.76▼$19.35$48.02M1.25116,069 shs7,600 shsDAREDare Bioscience$2.74-5.9%$1.87$1.27▼$9.19$39.60M1.09372,798 shs235,561 shsGTBPGT Biopharma$0.38-1.9%$0.41$0.26▼$3.85$13.50M0.641.03 million shs108,749 shsLIXTLixte Biotechnology$5.07+2.9%$3.17$0.64▼$6.26$58.93M1.0460,826 shs11,962 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.24%+5.59%+16.19%+6.18%-53.39%DAREDare Bioscience-7.91%+27.63%+64.41%+72.19%+0.66%GTBPGT Biopharma-3.28%+26.38%-5.76%-27.72%-83.39%LIXTLixte Biotechnology+12.05%+40.86%+72.98%+67.12%+313.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.40Hold$36.33551.49% UpsideDAREDare Bioscience 2.33Hold$10.00265.36% UpsideGTBPGT Biopharma 1.00SellN/AN/ALIXTLixte Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GTBP, ATOS, DARE, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ATOSAtossa Genetics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$120.00 ➝ $24.003/26/2026ATOSAtossa Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/ADAREDare Bioscience$1.03M38.68N/AN/A$0.20 per share13.69GTBPGT BiopharmaN/AN/A$0.01 per share26.92$0.23 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.60N/AN/AN/AN/A-65.56%-57.74%5/8/2026 (Estimated)DAREDare Bioscience-$13.40M-$1.25N/AN/AN/AN/AN/A-56.52%5/12/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.55N/AN/AN/AN/AN/A-116.67%5/21/2026 (Estimated)LIXTLixte Biotechnology-$6.01M-$1.24N/AN/AN/AN/A-242.85%-115.18%5/11/2026 (Estimated)Latest GTBP, ATOS, DARE, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GTBPGT Biopharma-$0.08N/AN/AN/AN/AN/A5/12/2026Q1 2026DAREDare Bioscience-$0.33N/AN/AN/A$0.03 millionN/A5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/A3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A5.535.53DAREDare BioscienceN/A1.141.14GTBPGT BiopharmaN/A3.503.50LIXTLixte BiotechnologyN/A3.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%DAREDare Bioscience6.70%GTBPGT Biopharma8.15%LIXTLixte Biotechnology5.10%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%DAREDare Bioscience4.80%GTBPGT Biopharma3.40%LIXTLixte Biotechnology9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableDAREDare Bioscience3014.56 million13.86 millionNot OptionableGTBPGT Biopharma835.62 million34.41 millionNo DataLIXTLixte Biotechnology411.62 million10.51 millionNot OptionableGTBP, ATOS, DARE, and LIXT HeadlinesRecent News About These CompaniesLIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 28, 2026 | finance.yahoo.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 27, 2026 | financial-news.co.ukLIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment LandscapeApril 21, 2026 | financial-news.co.ukLixte Biotechnology Updates Executive Equity Compensation With RSUsApril 17, 2026 | tipranks.comLIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO ConferenceApril 13, 2026 | usatoday.comFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceApril 13, 2026 | globenewswire.comLixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | financial-news.co.ukLixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | finance.yahoo.comLixte Biotechnology Holdings, Inc.April 7, 2026 | cnn.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational YearApril 4, 2026 | usatoday.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearApril 1, 2026 | finanznachrichten.deLIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment OutcomesApril 1, 2026 | financial-news.co.ukLIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment OutcomesApril 1, 2026 | finance.yahoo.comLIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical TrialsApril 1, 2026 | financial-news.co.ukLIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical TrialsApril 1, 2026 | finance.yahoo.comLIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearMarch 31, 2026 | globenewswire.comLixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies PartnershipMarch 27, 2026 | financial-news.co.ukLandmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It ComingMarch 25, 2026 | finance.yahoo.comLIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology LandscapeMarch 23, 2026 | finance.yahoo.comLixte Biotechnology Raises CEO Compensation Amid Leadership SupportMarch 20, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Defense Budget Expansion: 3 Mid-Cap Names in a Sweet Spot By Chris Markoch | April 20, 2026The Drone Disruptor: Kratos Stock Seeks a Higher Altitude By Jeffrey Neal Johnson | April 8, 2026GTBP, ATOS, DARE, and LIXT Company DescriptionsAtossa Genetics NASDAQ:ATOS$5.58 -0.09 (-1.64%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Dare Bioscience NASDAQ:DARE$2.74 -0.17 (-5.95%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.GT Biopharma NASDAQ:GTBP$0.38 -0.01 (-1.93%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Lixte Biotechnology NASDAQ:LIXT$5.07 +0.14 (+2.86%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
